PHIO
Phio Pharmaceuticals Corp.
NasdaqCMUSDEQUITY
DELAYED
Last price
1.16
▼ 0.05 (4.13%)
MARKET · —
Price
Open
1.23
Prev close
1.21
Day high
1.24
Day low
1.17
Volume
138.29K
Market cap
—
P/E (TTM)
—
52W range
0.81 – 4.19
Trailing performance
Returnvs SPY
1W
+8.26%
+9.6%
1M
+10.28%
+6.5%
3M
+8.26%
+5.2%
6M
+14.56%
+3.5%
YTD
+12.38%
+0.1%
1Y
-41.87%
-61.9%
3Y
-94.07%
-168.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.11
+4.88% from price
SMA 20
1.07
+10.18% from price
SMA 50
1.05
+12.68% from price
SMA 100
1.11
+4.75% from price
SMA 200
1.14
+3.18% from price
EMA 12
1.11
+4.55% from price
EMA 26
1.08
+7.40% from price
EMA 50
1.07
+8.06% from price
RSI (14)
62.5
Neutral
MACD (12,26,9)
0.03
Hist 0.01
ATR (14)
0.06
5.39% of price
Realised vol 30D
73.9%
Annualised
Bollinger upper
1.18
20, 2σ
Bollinger lower
0.96
20, 2σ
50 / 200 cross
Death
1.05 vs 1.14
Trend bias
Above 200
+3.18%
Risk profile
Beta vs SPY
1.27
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
73.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-65.4%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.06
5.39% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
TMX Newsfile · 11d ago
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
TMX Newsfile · 16d ago
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
TMX Newsfile · 31d ago
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
TMX Newsfile · 31d ago
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
TMX Newsfile · 32d ago
Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones
InvestorsHub · 38d ago
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
TMX Newsfile · 38d ago
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
GlobeNewswire · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.